Display options
Cite
Deb P, Chakrabarti P, Chakrabarty S, et al. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol. 2014;35(1):26-30doi: 10.4103/0971-5851.133707.
Deb, P., Chakrabarti, P., Chakrabarty, S., Aich, R., Nath, U., Ray, S. S., & Chaudhuri, U. (2014). Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 35(1), 26-30. https://doi.org/10.4103/0971-5851.133707
Deb, Pratik, et al. "Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 35,1 (2014): 26-30. doi: https://doi.org/10.4103/0971-5851.133707
Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS, Chaudhuri U. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol. 2014 Jan;35(1):26-30. doi: 10.4103/0971-5851.133707. PMID: 25006280; PMCID: PMC4080658.
Copy Download .nbib Format: NLM
Share it on

Indian J Med Paediatr Oncol. 2014 Jan;35(1):26-30. doi: 10.4103/0971-5851.133707.

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Pratik Deb, Prantar Chakrabarti, Shila Chakrabarty, Rajarshi Aich, Uttam Nath, Siddhartha Sankar Ray, Utpal Chaudhuri

Affiliations

  1. Institute of Hematology and Transfusion Medicine, Medical College, Kolkata, West Bengal, India.

PMID: 25006280 PMCID: PMC4080658 DOI: 10.4103/0971-5851.133707

Abstract

CONTEXT: The exact role of the different transcript variants of BCR-ABL in the pathogenesis of chronic myeloid leukemia (CML) and their impact on prognosis is yet to be definitely enumerated.

AIMS: In this study, we have tried to correlate the presenting features, risk scores and treatment response with the BCR-ABL variants detected in our patients.

SETTINGS AND DESIGN: A cross-sectional unicentric hospital-based study on 80 patients diagnosed to have CML by bone marrow cytogenetics and confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR).

MATERIALS AND METHODS: RT-PCR for BCR-ABL was performed on consecutive patients with CML attending the CML clinic from January 2010 to December 2010. The medical charts of these patients were analyzed after a follow-up of 18 months in a retrospective manner.

STATISTICAL ANALYSIS: Box plot and histogram was used to see the distribution of variables. t-test was performed to enumerate the difference between risk scores in two populations of patients carrying two different BCR-ABL transcript variants.

RESULTS: Nearly 56.25% of patients had b3a2 (e14a2) while 41.25% of patients showed b2a2 (e13a2) transcripts. The rest 2.5% (two patients) expressed the rare e19b2 variant. Patients with b2a2 presented with higher Sokal, Hasford and European Treatment and Outcomes Study score than their b3a2 counterpart. Different parameters such as the platelet count, leukocyte count, hemoglobin and splenomegaly showed a minor difference between the groups. More patients in the b2a2 group achieved complete hematologic response at 3 months, but it was not significant.

CONCLUSIONS: Patients with b2a2 variant CML tend to present with higher risk score, but do not behave in a vastly different manner than their b3a2 counterparts.

Keywords: BCR-ABL transcript variants; chronic myeloid leukemia; chronic myeloid leukemia risk scores; imatinib mesylate

References

  1. Gac Med Mex. 2003 Nov-Dec;139(6):553-9 - PubMed
  2. Haematologica. 2002 Jun;87(6):666-8 - PubMed
  3. Cancer. 1995 Sep 15;76(6):992-7 - PubMed
  4. Leukemia. 1999 Dec;13(12):1901-28 - PubMed
  5. Blood. 1984 Apr;63(4):789-99 - PubMed
  6. Nature. 1985 Jun 13-19;315(6020):550-4 - PubMed
  7. Br J Haematol. 1995 Mar;89(3):546-54 - PubMed
  8. Science. 1986 Jul 11;233(4760):212-4 - PubMed
  9. Nat Rev Cancer. 2005 Mar;5(3):172-83 - PubMed
  10. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8 - PubMed
  11. J Clin Oncol. 2009 Dec 10;27(35):6041-51 - PubMed
  12. J Med Assoc Thai. 2000 Aug;83(8):928-35 - PubMed
  13. Hematol Rep. 2011 Jan 13;3(1):e3 - PubMed
  14. Blood. 2011 Jul 21;118(3):686-92 - PubMed
  15. Eur J Cancer. 2000 Jul;36(11):1395-401 - PubMed
  16. Haematologica. 2009 Oct;94(10):1362-7 - PubMed
  17. Blut. 1962 Apr;8:65-6 - PubMed
  18. Blood. 1991 Dec 15;78(12):3125-7 - PubMed
  19. Blood. 2006 Sep 15;108(6):1809-20 - PubMed
  20. Transl Res. 2006 Nov;148(5):249-56 - PubMed
  21. Genet Mol Res. 2005 Dec 30;4(4):803-11 - PubMed

Publication Types